Fumaric acid esters for psoriasis: a systematic review

Conclusion In conclusion, the use of FAE in the management of moderate to severe psoriasis is a promising treatment option, especially for those patients intolerant of, or unresponsive to other agents. If blood parameters are closely monitored during treatment as per the European Medicine Agencies guidelines (European Medicines Agency, ‘Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera’, http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/10/WC500196017.pdf, 2015) they may be safely used in practice. The licensing of FAEs in Ireland for the treatment of moderate to severe psoriasis would be desirable, increasing available treatment options.
Source: Irish Journal of Medical Science - Category: Journals (General) Source Type: research